Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Heba A. Elhady1,2*, Refat El-Sayed1,3 and Hamedah S. Al-nathali1

Abstract
A novel series of substituted 2-thiohydantoin incorporated with benzoimidazole, pyrazole, triazole and/or benzoxazole moieties has been synthesized using (E)-3-[1-(4-bromophenyl)ethylideneamino]-2-thioxoimidazolidin-4-one 1 as the key starting material. The key material 1 also reacted with an acetic anhydride, aromatic aldehydes, secondary amines, formaldehyde and triethyl orthoformate to give the corresponding acetyl, chalcone, Mannich bases and ethoxymethylene derivatives, respectively. The structures of the novel compounds were confirmed by spectral data and elemental analysis. The cytotoxic activity of all synthesized compounds was assessed in vitro against human hepatocellular cancer cell line (HePG-2) and breast carcinoma cell line (MCF-7). The bioassay results revealed that compound 14 has the best activity against HePG-2 cell line (IC50 = 2.33 μg/mL), while compound 5 has the best activity against MCF-7 cell line (IC50 = 3.98 μg/mL).

Keywords: 2-Thiohydantoin, Benzoimidazole, Benzoxazole, Pyrazole, HEPG-2 cell line and MCF-7 cell line

Introduction
2-Thioxoimidazolidin-4-one ring (2-thiohydantoin) has been extensively studied. This five-membered heterocyclic ring is present in a wide range of biologically active compounds. The biological activities have been shown by some of their derivatives are mainly, anticonvulsant [1], antiviral [2], antiproliferative [3], anticancer [4–9], antibacterial, antifungal [10], anxiolytic [11], antidiabetic activity [12] and also used as inhibitor of a fatty acid amide hydrolase [13]. Additionally, 2-thiohydantoins are used in synthetic chemistry as in skin hyperpigmentation applications [14], in the production of antimicrobial polyurethane coatings [15], in textile printing, polymerization catalysis [16] and as a reagent for development of dyes [17]. The observed activities arise from the thiohydantoin heterocycle, but the different substituents attached to it are determinant in these properties. Diverse applications of 2-thioxoimidazolidin-4-one in drug field have encouraged the medicinal chemists to synthesize and evaluate a large number of novel molecules. In this research point, we design new compounds based on the biological activity of other heterocycles such as pyrazoles [18, 19], triazoles [20, 21], benzimidazole [22], benzoxazole [23] and Schiff bases [24–26] in the field of cancer and microbial therapy. As an extension of our work on the synthesis of heterocyclic systems and evaluation of their biological activity [27–33], we reported here the synthesis of some novel substituted 2-thiohydantoin and evaluate their cytotoxic activity. (E)-3-[1-(4-bromophenyl) ethylideneamino]-2-thioxoimidazolidin-4-one 1 was prepared and used as the building block for the synthesis of the novel compounds.

Results and discussion
Chemistry
As an extension of our interest on the chemistry of 2-thiohydantoin, we reported here the synthesis of
novel derivatives using (E)-3-[1-(4-bromophenyl)ethylideneamino]-2-thioximidazolidin-4-one 1 as the key starting material. Compound 1 was prepared via reaction of (E)-2-[1-(4-bromophenyl)ethylidene]hydrazinecarbothioamide in the presence of sodium acetate [27, 28]. Alkylation of 1 with ethyl chloroacetate in the presence of anhydrous potassium carbonate gave (E)-ethyl 2-[3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioximidazolidin-1-yl]acetate 2. The structure of 2 was confirmed by spectral data, elemental analysis and chemical transformation. Thus, hydrolysis of the ester 2 with 2 N sodium hydroxide gave (E)-2-[3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioximidazolidin-1-yl]acetic acid 3. Hydrazinolysis of 2 with hydrazine hydrate in ethanol (E)-2-[3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioximidazolidin-1-yl]acetohydrazide 4, which is a suitable intermediate for the synthesis of the target compounds (Scheme 1). Cyclization of 4 with ethyl acetooacetate, acetylatedone and/or ethyl cyanoacetate in acetic acid gave the corresponding pyrazole derivatives 5, 6 and pyrazole-3,5-dione derivative 7, respectively. Also, reaction of 4 with ethoxymethylene malononitrile (EMM) in ethanol under reflux gave pyrazole-4-carbonitrile derivative 8 (Scheme 2).

To obtain a series of biologically active compounds, compound 4 was treated with phenylisothiocyanate in dimethylformamide to afford 9, which cyclized with 5% alcoholic sodium hydroxide to give 4-phenyl-5-thioxo-1,2,4-triazole derivative 10. Moreover, condensation of 4 with different aromatic aldehydes namely, isonicotinaldehyde and 4-hydroxy-3-methoxybenzaldehyde in ethanol in the presence of piperidine under reflux led to the formation of Schiff bases 11a, b (Scheme 3).

To obtain substituted 2-thiohydantoin derivatives incorporated with benzimidazole and/or benzoxazole moieties, compound 1 was reacted with triethyl orthoformate and/or diethyl oxalate in xylene in the presence of sodium metal under reflux to give 12 and/or 13, respectively. Compound 13 was condensed with α-phenlenediamine and/or 2-aminophenol in acetic acid under fusion to give 14 and/or 15, respectively (Scheme 4). Moreover, new series of biologically active 2-thiohydantoin derivatives were prepared by acetylation of 1 with acetic anhydride to give 16 and 17. Condensation of 16 with aldehydes such as vanillin in the presence of piperidine under fusion gave chalcone derivative 18. Also, Mannich base was prepared by reacting 1 with diethylamine and formaldehyde in ethanol to give 19. Finally, hydrazinolysis of 1 with hydrazine hydrate in ethanol gave 20 (Scheme 5). The structures of the synthesized compounds were confirmed by spectral data and elemental analysis.

Biological assessment

In vitro anticancer screening

The anti-tumor activity of all synthesized compounds has been evaluated against two cell lines HepG-2 cells (human hepatocellular cancer cell line), and MCF-7 (breast carcinoma cell line) [34–36]. The cell lines were obtained from VACSERA Tissue Culture Unit, and the experiments were performed by the Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt. Different concentrations of the tested samples (500, 250, 125, 62.5, 31.25, 15.6, 7.8, 3.9, 2 and 1 μg/mL) were used to detect the inhibitory activity. Cell viability (%) was determined by colorimetric method. Doxorubicin was used as the reference drug, as it is one of the most effective anticancer agents. The relationship between drug concentration and cell viability was plotted to obtain the survival curve of hepatocellular carcinoma cell line HePG2 and breast cancer cell line MCF-7. The IC50 value, which corresponds to the concentration required for 50% inhibition of cell viability was calculated.

Tables 1, 2, 3 show the in vitro cytotoxicity of the synthesized compounds against hepatocellular carcinoma cell line HePG-2. Tables 4, 5, 6 show the in vitro cytotoxicity against breast carcinoma cell line MCF-7. Data examination revealed that the tested compounds showed good to moderate activity. Compound 14 has the best activity against HePG-2 cell line (IC50 = 2.33 μg/mL), while, compound 5 has the best activity against MCF-7 cell line (IC50 = 3.98 μg/mL) and compound 11a has the lowest activity against HePG-2 cell line (IC50 = 243 μg/mL) and against MCF-7 cell line (IC50 = 249 μg/mL). The structure and biological activity relationship of the title compound 1 showed that, the activity of thiohydantoin diverse with the substituents on it, where introducing active groups such as, CH3CO, OH, OCH3, OC2H5, =CH-OC2H5 enhanced the activity, also, the presence of benzimidazole, pyrazolone, pyrazole carbonitrile and triazine moieties enhanced the activity of thiohydantoin, while the activity was decreased by introducing benzoxazole, pyrazolinedinedioxide moieties and Schiff bases. Alkylation of thiohydantoin decreases the activity; however, when the ester 2 was reacted with hydrazine hydrate to form the acid hydrazide 4 the activity was enhanced especially against MCF-7 cell line.

The resulting data of the 50% inhibition concentration (IC50) summarized in Table 7 showed that, the synthesized compounds have different activity against hepatocellular carcinoma cell line HePG2 and breast cancer cell line MCF-7.

Page 2 of 13

Elhady et al. Chemistry Central Journal (2018) 12:51
Conclusion

A novel series of substituted 2-thiohydantoin with incorporated benzimidazole, pyrazole, triazole and/or benoxazole moieties has been synthesized. The structures of these compounds were confirmed by IR, $^1$HNMR, $^{13}$CNMR, MS and elemental analysis. The bioassay results revealed that, Compound 14 has the best activity against HePG2 cell line ($IC_{50} = 2.33$ μg/mL), while compound 5 has the best activity against MCF-7 cell line ($IC_{50} = 3.98$ μg/mL). Structure and biological activity relationship showed that, the activity of thiohydantoin diverse with the substituents on it, where introducing active groups such as, CH$_3$CO, OH, OCH$_3$, O$_2$H$_3$, =CH–O=C$_2$H$_5$ and the presence of benzimidazole, pyrazolone, pyrazole carbonitrile and triazine moieties enhanced the activity of thiohydantoin.
Experimental section

Melting points were measured using electrothermal digital melting points apparatus and are uncorrected. IR (infrared) spectra were recorded on NICOLET (iS50 FT-IR) spectrometer using KBr pellets. $^1$H and $^{13}$C NMR (nuclear magnetic resonance) were recorded on a Bruker AS 850 TM spectrometer at 850 MHz and chemical shifts were given with respect to TMS (tetramethylsilane). Mass (MS) spectra were recorded on GC/MS with CI (chemical ionization) and a Hewlett-Packard MS Engine Thermospray and ionization by electron impact to (70 eV). Microanalysis was conducted using elemental analyzer 106.

Synthesis of (E)-3-[1-(4-bromophenyl)ethylideneamino]-2-thioxoimidazolidin-4-one 1

A mixture of (E)-2-[1-(4-bromophenyl)ethylidene]hydrazinecarbothioamide (0.01 mol) and ethyl chloroacetate (0.01 mol) in ethanol (50 mL) in the presence of fused sodium acetate (0.03 mol) was heated under reflux for 2 h, then cooled and poured into water. The solid formed was filtered off, washed with water, dried and purified from ethanol to give 1.

Synthesis of (E)-ethyl 2-[3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioxoimidazolidin-1-yl]acetate 2

A mixture of 1 (0.01 mol), ethyl chloroacetate (0.01 mol) and anhydrous potassium carbonate (0.015 mol) in 20 mL ethanol was stirred under reflux for 6 h. The reaction mixture was poured into an ice-water mixture. The solid product separated was filtered off, washed with water, dried and crystallized from ethanol to give 2 as pale yellow crystals, in yield 92%, m.p 78–80 °C. $^1$H-NMR (DMSO-d$_6$): $\delta$ = 7.79 (d, 2H, $J$ = 8.5 Hz, 2CH), 7.65 (d, 2H, $J$ = 8.5 Hz, 2H, 2CH), 4.52 (s, 2H, CH$_2$), 4.16 (q, 2H, $J$ = 6.8 Hz, CH$_3$), 4.10 (s, 2H, CH$_2$), 2.34 (s, 3H, CH$_3$) and 1.20 (t, 3H, $J$ = 6.8 Hz, CH$_3$) ppm. $^{13}$C-NMR (DMSO-d$_6$): $\delta$ = 171.68 (C=S), 166.96, 162.10 (2C=O), 161.40 (C=N), 136.65, 131.46, 128.48, 123.66 (C-aromatic), 61.23 (CH$_2$), 58.94 (CH$_2$), 32.11 (CH$_2$), 14.33 (CH$_3$), 14.24 (CH$_3$) ppm. IR (KBr): 1742, 1711 (2C=O), 1611 (C=N) and 1386 (C=S) cm$^{-1}$. MS: m/z (%): 398 (31), 397 (M$^+$, 79Br, 100) and 399 (M$^+$, 81Br, 80). Anal. Calcd. C$_{15}$H$_{16}$BrN$_3$O$_3$S (398.27): C, 45.24; H, 4.05; Br, 20.06; N, 10.55; S, 8.05%. Found. C, 45.30; H, 4.11; Br, 19.97; N, 10.47; S, 8.10.

Synthesis of (E)-2-[3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioxoimidazolidin-1-yl]acetic acid 3

Sodium hydroxide (30 mL/4 N) was added to a solution of 2 (0.01 mol) in ethanol (30 mL), then heated under reflux for 2 h. The reaction mixture was cooled and acidified with 2 N hydrochloric acid. The solid formed was filtered off, washed with water, dried and purified from ethanol to give 3 as pale yellow crystals, in yield 52%, m.p 213–215 °C. $^1$H-NMR (DMSO-d$_6$): $\delta$ = 9.37 (br. s, 1H, OH), 7.70 (d, 2H, $J$ = 8.5 Hz, 2CH), 7.57 (d, 2H, $J$ = 8.5 Hz, 2CH), 4.53 (s, 2H, CH$_2$), 3.85 (s, 2H, CH$_2$), 1.28 (s, 2H, CH$_2$) ppm. IR (KBr): 3424, 3260 (OH), 1705 (C=O), 1604 (C=N). MS: m/z (%): 264 (41, M$^+$, 79Br, 100) and 266 (M$^+$, 81Br, 80). Anal. Calcd. C$_{15}$H$_{15}$BrN$_3$O$_3$S (398.27): C, 45.24; H, 4.05; Br, 20.06; N, 10.55; S, 8.05%. Found. C, 45.30; H, 4.11; Br, 19.97; N, 10.47; S, 8.10.

Scheme 3 Synthesis of compounds 9, 10 and 11 a, b
$^{3}$H, $^3$CH$_3$ ppm. $^{13}$C-NMR (DMSO-$d_6$): $\delta$ = 173.45 (C=S), 168.83, 165.20 (2C=O), 157.19 (C=N), 131.77, 130.78, 128.70, 126.03 (C-aromatic), 75.1 (CH$_2$), 29.81 (CH$_2$) and 14.03 (CH$_3$) ppm. IR (KBr): 3308 (br. OH), 1725, 1675 (2C=O), 1617 (C=N) and 1393 (C=S) cm$^{-1}$. MS: m/z (%): 370 (4), 369 (M$^+$, 79Br, 14), 371 (M$^+$, 81Br, 1), 368 (M$^+$ − 1, 34) and 57 (100). Anal. Calcd. C$_{13}$H$_{13}$BrN$_3$O$_3$S (370.22): C, 42.17; H, 3.27; Br, 21.58; N, 11.35; S, 8.66. Found. C, 42.27; H, 3.29; Br, 21.71; N, 11.48; S, 8.59.

**Synthesis of (E)-2-[3-[1-(4-bromophenyl) ethylideneamino]-4-oxo-2-thioxoimidazolidin-1-yl]acetohydrazide 4**

A mixture of 3 (0.01 mol) and hydrazine hydrate (0.03 mol) in ethanol (20 mL), was heated under reflux for 2 h, the reaction mixture was cooled, then poured into ice/water solution and acidified with hydrochloric acid (1 N). The resulting solid was filtered off, washed with water, dried and crystallized from ethanol to give 4 as white crystals, in yield 85%, m.p 196–198 °C. $^1$H-NMR (DMSO-$d_6$): $\delta$ = 10.25 (s, 1H, NH), 8.30 (s, 2H, NH$_2$), 7.90 (d, 2H, $J = 8.5$ Hz, 2CH), 7.78 (d, 2H, $J = 8.5$ Hz, 2CH), 4.43 (s, 2H, CH$_2$), 4.07 (s, 2H, CH$_2$) and 2.35 (s, 3H, CH$_3$) ppm. $^{13}$C-NMR (DMSO-$d_6$): $\delta$ = 171.67 (C=S), 166.96, 165.43 (2C=O), 161.36 (C=N), 136.69, 131.45, 128.44, 123.67 (C-aromatic), 61.28, 44.32 (2CH$_2$), and 14.38 (CH$_3$). IR (KBr): 3407 (NH), 3225, 3190 (NH$_2$), 1716, 1669 (2C=O), 1584 (C=N) and 1393 (C=S) cm$^{-1}$. MS: m/z (%): 384 (34), 383 (M$^+$, 79Br, 5), 385 (M$^+$, 81Br, 15) and 381 (100). Anal. Calcd. C$_{13}$H$_{14}$BrN$_5$O$_2$S (384.25): C, 40.63; H, 3.67; Br, 20.79; N, 18.23; S, 8.34. Found. C, 40.69; H, 3.56; Br, 20.75; N, 18.35; S, 8.27.

**Typical procedure for syntheses of compounds 5–7**

A mixture of compound 4 (0.01 mol) and an equimolar amount of ethyl acetoacetate or acetylacetone or ethyl cyanoacetate (or diethyl malonate) was refluxed in 10 mL of acetic acid for 5 h. The product formed after cooling was filtered off, washed with water, dried and crystallized with acetic acid to give compounds 5, 6, and 7, respectively.
Scheme 5 Synthesis of compounds 16, 17, 18, 19 and 20

Table 1 Cytotoxicity of compounds 1, 2, 3, 4, 5, 6, 7 and 8 against hepatocellular carcinoma cell line HePG2

| Concentration µg/mL | Viability (%) | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  |
|---------------------|--------------|----|----|----|----|----|----|----|----|
| 500                 |              | 5.26 | 19.86 | 2.97 | 7.48 | 3.04 | 31.67 | 12.58 | 6.31 |
| 250                 |              | 10.68 | 28.74 | 7.28 | 14.53 | 6.31 | 46.23 | 20.64 | 14.96 |
| 125                 |              | 18.97 | 39.45 | 11.49 | 21.84 | 10.25 | 68.92 | 31.75 | 20.85 |
| 62.5                |              | 25.14 | 68.17 | 16.85 | 29.41 | 16.43 | 83.64 | 42.31 | 26.43 |
| 31.25               |              | 34.72 | 79.52 | 23.72 | 38.63 | 22.37 | 93.51 | 64.15 | 38.14 |
| 15.6                |              | 48.25 | 91.43 | 30.85 | 49.56 | 30.69 | 99.48 | 79.27 | 47.59 |
| 7.8                 |              | 62.89 | 98.76 | 41.93 | 71.38 | 38.15 | 100  | 88.74 | 60.31 |
| 3.9                 |              | 78.03 | 100  | 51.58 | 85.97 | 46.36 | 100  | 96.13 | 73.86 |
| 2                   |              | 86.26 | 100  | 62.72 | 92.04 | 59.02 | 100  | 99.47 | 85.23 |
| 1                   |              | 90.41 | 100  | 70.88 | 97.13 | 74.15 | 100  | 100  | 90.67 |
| 0                   |              | 100  | 100  | 100  | 100  | 100  | 100  | 100  | 100  |
Table 2  Cytotoxicity of compounds 9, 10, 11a, 11b, 12, 13, and 14 against hepatocellular carcinoma cell line HePG2

| Concentration µg/mL | Viability (%)/compound |
|---------------------|------------------------|
|                     | 9  | 10  | 11a | 11b | 12  | 13  | 14  |
| 500                 | 8.43 | 8.32 | 23.84 | 10.32 | 4.29 | 4.83 | 3.74 |
| 250                 | 15.82 | 16.01 | 48.67 | 19.47 | 11.82 | 12.56 | 8.91 |
| 125                 | 24.67 | 23.65 | 72.89 | 27.93 | 20.49 | 19.74 | 14.82 |
| 62.5                | 30.93 | 29.86 | 90.31 | 38.76 | 26.54 | 28.63 | 20.94 |
| 31.25               | 41.28 | 37.40 | 98.16 | 50.37 | 32.75 | 35.16 | 25.86 |
| 15.6                | 48.71 | 46.89 | 100  | 68.24 | 41.87 | 46.29 | 31.43 |
| 7.8                 | 62.39 | 58.62 | 100  | 81.49 | 55.46 | 57.18 | 37.82 |
| 3.9                 | 78.24 | 73.94 | 100  | 90.65 | 73.82 | 70.42 | 45.27 |
| 2                   | 88.65 | 81.47 | 100  | 97.34 | 81.46 | 83.29 | 50.94 |
| 1                   | 94.27 | 89.53 | 100  | 88.73 | 89.64 | 62.35 | 100  |
| 0                   | 100  | 100  | 100  | 100  | 100  | 100  | 100  |

Table 3  Cytotoxicity of compounds 15, 16, 17, 18, 19, 20 and Doxorubicin against hepatocellular carcinoma cell line HePG2

| Concentration µg/mL | Viability (%)/compound |
|---------------------|------------------------|
|                     | 15 | 16 | 17 | 18 | 19 | 20 | Doxorubicin |
| 500                 | 6.49 | 4.31 | 6.78 | 4.68 | 3.84 | 6.91 | 3.6 |
| 250                 | 11.25 | 11.72 | 15.93 | 10.35 | 9.65 | 11.76 | 3.97 |
| 125                 | 19.43 | 18.25 | 24.85 | 17.46 | 13.81 | 20.95 | 6.43 |
| 62.5                | 30.61 | 23.87 | 34.91 | 25.72 | 19.46 | 32.47 | 9.68 |
| 31.25               | 39.45 | 30.64 | 42.87 | 32.69 | 25.83 | 44.35 | 16.45 |
| 15.6                | 51.26 | 38.92 | 67.29 | 44.82 | 32.17 | 76.97 | 23.87 |
| 7.8                 | 67.18 | 47.30 | 83.97 | 51.96 | 39.68 | 89.50 | 30.69 |
| 3.9                 | 84.91 | 64.59 | 91.48 | 64.53 | 48.54 | 94.16 | 37.54 |
| 2                   | 92.73 | 76.28 | 98.02 | 72.31 | 61.83 | 98.73 | 42.91 |
| 1                   | 96.48 | 81.49 | 100  | 79.48 | 69.42 | 100  | 48.76 |
| 0                   | 100  | 100  | 100  | 100  | 100  | 100  | 100  |

Table 4  Cytotoxicity of compounds 1, 2, 3, 4, 5, 6, 7 and 8 against breast carcinoma cell line MCF-7

| Concentration µg/mL | Viability (%)/compound |
|---------------------|------------------------|
|                     | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 500                 | 7.18 | 22.34 | 3.86 | 9.26 | 4.23 | 37.15 | 16.27 | 8.07 |
| 250                 | 13.95 | 34.51 | 9.62 | 20.84 | 9.06 | 51.49 | 29.38 | 16.56 |
| 125                 | 24.82 | 45.28 | 14.87 | 28.63 | 15.38 | 74.01 | 38.69 | 24.56 |
| 62.5                | 32.93 | 73.69 | 20.65 | 36.59 | 21.75 | 88.63 | 49.16 | 31.88 |
| 31.25               | 45.06 | 86.13 | 26.83 | 42.67 | 28.91 | 97.89 | 71.32 | 40.31 |
| 15.6                | 60.83 | 94.56 | 36.54 | 48.54 | 36.42 | 100  | 86.04 | 52.76 |
| 7.8                 | 79.62 | 98.94 | 45.02 | 65.18 | 42.37 | 100  | 93.76 | 68.49 |
| 3.9                 | 85.21 | 100  | 60.89 | 80.95 | 50.16 | 100  | 98.51 | 82.53 |
| 2                   | 92.37 | 100  | 78.15 | 91.79 | 65.24 | 100  | 100  | 91.42 |
| 1                   | 98.64 | 100  | 86.41 | 95.48 | 76.35 | 100  | 100  | 97.17 |
| 0                   | 100  | 100  | 100  | 100  | 100  | 100  | 100  | 100  |
(E)-1-(2-[(4-bromophenyl)ethylideneamino]-4-oxo-2-thioxoimidazolidin-1-yl)acetyl)-3-methyl-1H-pyrazol-5(4H)-one 5 Yellow crystals, in yield 74%, m.p 177–179 °C. 1H-NMR (DMSO-$d_6$): $\delta$ = 7.74 (d, 2H, $J = 8.5$ Hz, 2CH), 7.65 (d, 2H, $J = 8.5$ Hz, 2CH), 4.52 (s, 2H, CH2), 4.09 (s, 2H, CH2), 3.89 (s, 2H, CH2), 2.34 (s, 3H, CH3) and 1.89 (s, 3H, CH3) ppm. 13C-NMR (DMSO-$d_6$): $\delta$ = 171.73 (C=S), 168.02, 167.01, 164.60 (3C=O), 161.47, 161.29 (C=N), 136.68, 131.43, 128.53, 123.71 (C-aromatic), 61.33, 43.80, 32.16 (3CH2) and 20.47, 14.62 (2CH3). IR (KBr): 1716, 1741 (C=O), 1605, 1589 (2C=N) and 1386 (C=S) cm$^{-1}$. MS: m/z (%): 450 (13), 449 (M$^+$), 451 (M$^+$, 81Br, 7) and 427 (100). Anal. Calcd. C$_{17}$H$_{16}$BrN$_5$O$_3$S (450.31): C, 45.34; H, 3.58; Br, 17.74; N, 15.55; S, 7.12. Found. C, 45.38; H, 3.62; Br, 17.83; N, 15.49; S, 7.15.

Table 5 Cytotoxicity of compounds 9, 10, 11a, 11b, 12, 13, 14 and 15 against breast carcinoma cell line MCF-7

| Concentration µg/mL | Viability (%)/compound |
|---------------------|------------------------|
|                     | 9          | 10         | 11a        | 11b        | 12         | 13         | 14         |
| 500                 | 8.09      | 6.48       | 31.79      | 8.51       | 6.37       | 5.96       | 5.08       |
| 250                 | 17.24     | 15.72      | 49.81      | 20.38      | 14.75      | 11.74      | 10.24      |
| 125                 | 26.85     | 24.16      | 78.26      | 32.75      | 23.81      | 20.82      | 18.76      |
| 62.5                | 37.51     | 35.29      | 89.47      | 45.06      | 34.93      | 27.41      | 24.95      |
| 31.25               | 45.97     | 42.81      | 95.24      | 61.78      | 40.84      | 34.92      | 30.88      |
| 15.6                | 57.20     | 51.56      | 99.71      | 79.39      | 49.60      | 44.73      | 36.78      |
| 7.8                 | 74.19     | 69.37      | 100        | 92.64      | 70.38      | 65.46      | 42.97      |
| 3.9                 | 88.43     | 86.02      | 100        | 98.25      | 81.49      | 79.25      | 51.36      |
| 2                   | 95.72     | 93.88      | 100        | 100        | 92.63      | 90.48      | 59.28      |
| 1                   | 99.34     | 97.40      | 100        | 100        | 96.75      | 96.23      | 72.83      |
| 0                   | 100       | 100        | 100        | 100        | 100        | 100        | 100        |

Table 6 Cytotoxicity of compounds 15, 16, 17, 18, 19, 20 and Doxorubicin against breast carcinoma cell line MCF-7

| Concentration µg/mL | Viability (%)/compound |
|---------------------|------------------------|
|                     | 15         | 16         | 17         | 18         | 19         | 20         | Doxorubicin |
| 500                 | 8.76      | 5.28       | 7.95       | 6.17       | 5.21       | 8.25       | 1.51        |
| 250                 | 13.81     | 13.96      | 21.34      | 13.92      | 11.36      | 16.37      | 3.16        |
| 125                 | 26.92     | 21.47      | 30.67      | 21.40      | 20.84      | 28.72      | 3.21        |
| 62.5                | 37.24     | 32.68      | 38.72      | 28.57      | 27.30      | 41.89      | 5.07        |
| 31.25               | 48.17     | 36.43      | 51.90      | 36.71      | 35.26      | 49.78      | 6.93        |
| 15.6                | 60.95     | 42.90      | 64.18      | 48.86      | 39.48      | 80.93      | 15.46       |
| 7.8                 | 76.43     | 51.72      | 72.37      | 69.52      | 46.29      | 92.34      | 19.89       |
| 3.9                 | 89.71     | 69.37      | 88.45      | 81.94      | 54.68      | 97.28      | 24.98       |
| 2                   | 97.02     | 83.19      | 92.32      | 90.68      | 69.31      | 100        | 31.69       |
| 1                   | 100       | 92.48      | 97.45      | 96.25      | 80.47      | 100        | 40.17       |
| 0                   | 100       | 100        | 100        | 100        | 100        | 100        | 100         |

(E)-3-[1-(4-bromophenyl)ethylideneamino]-1-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]-2-thioxoimidazolidin-4-one 6 Black crystals, in yield 82%, m.p 83–85 °C. 1H-NMR (DMSO-$d_6$): $\delta$ = 7.89–7.65 (m, 5H, Ar–H), 4.52 (s, 2H, CH2), 4.10 (s, 2H, CH2), 2.57 (s, 3H, CH3), 2.34 (s, 3H, CH3) and 1.82 (s, 3H, CH3) ppm. 13C-NMR (DMSO-$d_6$): $\delta$ = 170.05 (C=S), 166.18, 164.60 (2C=O), 160.36, 160.19 (2C=N), 138.16, 138.08, 132.57, 132.14, 128.20, 123.43 (C-aromatic), 58.75, 31.19 (2CH2), 19.83, 16.34, 14.52 (2CH3) ppm. IR (KBr): 1722 (C=O), 1716, 1741 (C=O), 1605, 1589 (2C=N) and 1386 (C=S) cm$^{-1}$. MS: m/z (%): 448 (12), 447 (M$^+$, 79Br, 5) and 450 (M$^+$ + 1, 14), 76 (100). Anal. Calcd. C$_{18}$H$_{18}$BrN$_5$O$_2$S (448.34): C, 48.22; H, 4.05; Br, 17.82; N, 15.62; S, 7.15. Found. C, 48.31; H, 3.95; Br, 17.95; N, 15.70; S, 7.21.
(E)-1-(2-[(3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioxoimidazolidin-1-yl)acetyl]pyrazolidine-3,5-dione 7  
Pale yellow crystals, in yield 69%, m.p 228–230 °C.  
1H-NMR (DMSO-d6): δ = 10.81 (s, 1H, NH), 7.66 (d, 2H, J = 8.5 Hz, 2CH), 7.63 (d, 2H, J = 8.5 Hz, 2CH), 4.52 (s, 2H, CH2), 4.10 (s, 2H, CH2), 4.03 (s, 2H, CH2) and 2.34 (s, 3H, CH3) ppm.  
13C-NMR (DMSO-d6): δ = 174.12 (C=O), 169.25, 166.78, 165.44, 163.99 (4C=O), 159.89 (C=N), 132.41, 131.43, 128.45, 123.98 (C-aromatic), 58.55, 44.32, 31.73 (CH3) and 16.67 (CH3) ppm. IR (KBr): 1698, 1660, 1622, 1618, 1581 cm⁻¹. MS: m/z (%): 453 (6), 452 (M⁺, 79Br, 11) and 454 (M⁺, 81Br, 10) and 101 (100). Anal. Calcd. C16H13BrN5O4S (452.28): C, 42.49; H, 3.12; Br, 17.67; N, 15.48; S, 7.09. Found: C, 42.42; H, 3.15; Br, 17.60; N, 15.40; S, 7.11.

Synthesis of (E)-5-amino-1-(2-{3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioxoimidazolidin-1-yl}acetyl)-1H-pyrazole-4-carboxylate 8

To compound 4 (0.01 mol) dissolved in 50 mL absolute ethanol was added slowly with shaking, ethoxymethyleneonitrile (0.01 mol), after addition of about half of the quantity, the solution was gently heated to boiling. The remaining ethoxymethyleneonitrile was added, at such a rate to maintain gentle boiling of the solution, after all the ethoxymethyleneonitrile had been added, the solution was gently boiled for an additional 30 min and finally was set aside overnight in the refrigerator. The product formed was filtered off, dried and crystallized from ethanol to give 8 as yellow crystals, in yield 89%, m.p 68–70 °C.  
1H-NMR (DMSO-d6): δ = 11.06 (s, 1H, NH), 8.54 (s, 1H, NH), 9.86 (s, 1H, NH), 7.71–7.24 (m, 9H, Ar–H), 4.52 (s, 2H, CH2), 3.16 (s, 2H, CH2) and 2.33 (s, 3H, CH3) ppm.  
13C-NMR (DMSO-d6): δ = 174.12 (C=O), 169.25, 166.78, 165.44, 163.99 (4C=O), 159.89 (C=N), 132.41, 131.43, 128.45, 123.98 (C-aromatic), 58.55, 44.32, 31.73 (CH3) and 16.67 (CH3) ppm. IR (KBr): 3196, 1698, 1660, 1622, 1618, 1581 cm⁻¹. MS: m/z (%): 460 (5), 459 (M⁺, 79Br, 11), 461 (M⁺, 81Br, 10) and 383 (100). Anal. Calcd. C17H19BrN10O4S (460.31): C, 44.36; H, 3.07; Br, 17.36; N, 21.30; S, 6.97. Found. C, 44.52; H, 3.13; Br, 17.48; N, 21.27; S, 6.83.

Synthesis of (E)-2-(2-{3-[1-(4-bromophenyl)ethylideneamino]-4-oxo-2-thioxoimidazolidin-1-yl}acetyl)-N-phenylhydrazinecarbothioamide 9

A mixture of 4 (0.01 mol) and phenyl isothiocyanate (0.01 mol) in dimethylformamide (25 mL) was stirred under reflux for 5 h. The reaction mixture then cooled to room temperature, poured into ice water, then acidified with dilute hydrochloric acid. The resulting solid was filtered off, washed with water, dried and purified by crystallization from ethanol to give 9 as orange crystals, in yield 89%, m.p 68–70 °C.  
1H-NMR (DMSO-d6): δ = 11.06 (s, 1H, NH), 8.54 (s, 1H, NH), 9.86 (s, 1H, NH), 7.71–7.24 (m, 9H, Ar–H), 4.52 (s, 2H, CH2), 4.16 (s, 2H, CH2) and 2.33 (s, 3H, CH3) ppm. IR (KBr): 3198 (NH), 1653, 1723 (C=O), 1607 (C=N) and 1385 (C=S) cm⁻¹. MS: m/z (%): 519 (3), 518 (M⁺, 79Br, 6), 520 (M⁺, 81Br, 5) and 438 (100). Anal. Calcd. C24H19BrN10O4S2 (519.44): C, 46.24; H, 3.69; Br, 15.38; N, 16.18; S, 12.35. Found. C, 46.19; H, 3.59; Br, 15.52; N, 16.25; S, 12.39.

Synthesis of (E)-3-[3-(1-(4-bromophenyl)ethylideneamino)-1-{(4-phenyl-5-thiao-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl}-2-thioxoimidazolidin-4-one 10

A solution of 9 (0.01 mol) in ethanol (30 mL) was added with sodium hydroxide (30 mL/1 N), then heated under reflux for 4 h. The reaction mixture was cooled and acidified with dilute hydrochloric acid. The solid formed was filtered off, washed with water, dried and purified from ethanol to give 10 as white crystals, in yield 66%, m.p 48–50 °C.  
1H-NMR (DMSO-d6): δ = 11.05 (s, 1H, NH), 7.79–7.35 (m, 9H, Ar–H), 4.53 (s, 2H, CH2), 4.04 (s, 2H, CH2) and 2.26 (s, 3H, CH3) ppm.  
13C-NMR

Table 7 IC₅₀ of the tested compounds against hepatocellular carcinoma cell line HePG2 and breast cancer cell line MCF-7

| Compound no. | HepG-2 cell line | MCF-7 cell line |
|--------------|------------------|-----------------|
| 1            | 14.7             | 26.3            |
| 2            | 102              | 115             |
| 3            | 454              | 65.8            |
| 4            | 15.4             | 14.9            |
| 5            | 3.42             | 3.98            |
| 6            | 2.99             | 2.76            |
| 7            | 51.5             | 61.3            |
| 8            | 14.1             | 19.1            |
| 9            | 14.9             | 25.6            |
| 10           | 13.5             | 18.4            |
| 11a          | 243              | 249             |
| 11b          | 32.2             | 53.3            |
| 12           | 10.9             | 15.4            |
| 13           | 12.9             | 13.6            |
| 14           | 2.33             | 4.53            |
| 15           | 17.3             | 29              |
| 16           | 7.19             | 9.32            |
| 17           | 26.6             | 35.8            |
| 18           | 9.94             | 15.2            |
| 19           | 3.78             | 6.08            |
| 20           | 28.5             | 31.1            |
| Doxorubicin  | 0.85             | 0.35            |

Page 9 of 13

Elhady et al. Chemistry Central Journal (2018) 12:51
Syntheses of compounds 11a and 11b

A mixture of 4 (0.01 mol) and piperidine (1 mL) was fused on a hot plate at 100–110 °C for half an hour, then ethanol (25 mL) was added and refluxed for 2 h. The reaction mixture then cooled and acidified with diluted hydrochloric acid. The resulting solid was filtered off, washed with water, dried and purified by crystallization from proper solvent to give 11a, b.

(E)-2-[3-[1-(4-Bromophenyl)ethylideneamino]-4-oxo-2-thioxoimidazolidin-4-one 11b Pale yellow crystals, in yield 79%, m.p 161–163 °C. 1H-NMR (DMSO-d6): δ = 11.22 (s, 1H, NH), 7.74 (d, 2H, J = 8.5 Hz, 2CH2), 7.66 (2H, J = 8.5 Hz, 2CH2), 7.08 (s, 1H, =CHO), 4.15 (2H, J = 8.6 Hz, CH2), 2.29 (s, 3H, CH3) and 1.05 (t, 3H, J = 6.8 Hz, CH3) ppm. 13C-NMR (DMSO-d6): δ = 172.09 (C=S), 164.58 (C=O), 159.32 (C=N), 135.92 (CH), 133.99, 131.70, 128.24, 123.33 (C-aromatic), 115.45 (HNC=C), 65.57 (CH2) and 18.28, 14.32 (2CH3) ppm. IR (KBr): 1727, 1639, 1620, 1593, 1516, 1462, 1429, 1396, 1381, 1360, 1337, 1316, 1287, 1256, 1247, 1236, 1221, 1204, 1196, 1175, 1159, 1143, 1117, 1084, 1047, 1006, 978, 933, 900, 856, 821, 778, 749, 728, 661, 628, 592, 559, 526, 493, 461, 431, 406, 385, 364, 339 ppm.

Brown crystals, in yield 73%, m.p 238–240 °C. 1H-NMR (DMSO-d6): δ = 11.12 (s, 1H, NH), 7.74 (d, 2H, J = 8.5 Hz, 2CH2), 7.68 (d, 2H, J = 8.5 Hz, 2CH2), 7.08 (s, 1H, =CHO), 4.15 (2H, J = 8.6 Hz, CH2), 2.29 (s, 3H, CH3) and 1.05 (t, 3H, J = 6.8 Hz, CH3) ppm. 13C-NMR (DMSO-d6): δ = 172.09 (C=S), 164.58 (C=O), 159.13 (C=N), 135.92 (CH), 133.99, 131.70, 128.24, 123.33 (C-aromatic), 115.45 (HNC=C), 65.57 (CH2) and 18.28, 14.32 (2CH3) ppm. IR (KBr): 1727, 1639, 1620, 1593, 1516, 1462, 1429, 1396, 1381, 1360, 1337, 1316, 1287, 1256, 1247, 1236, 1221, 1204, 1196, 1175, 1159, 1143, 1117, 1084, 1047, 1006, 978, 933, 900, 856, 821, 778, 749, 728, 661, 628, 592, 559, 526, 493, 461, 431, 406, 385, 364, 339 ppm.

Brown crystals, in yield 69%, m.p 161–163 °C. 1H-NMR (DMSO-d6): δ = 12.00 (s, 1H, NH), 7.74 (d, 2H, J = 8.5 Hz, 2CH2), 7.66 (d, 2H, J = 8.5 Hz, 2CH2), 4.15 (2H, J = 8.6 Hz, CH2), 2.29 (s, 3H, CH3) and 1.05 (t, 3H, J = 6.8 Hz, CH3) ppm. 13C-NMR (DMSO-d6): δ = 172.09 (C=S), 164.58 (C=O), 159.13 (C=N), 135.92 (CH), 133.99, 131.70, 128.24, 123.33 (C-aromatic), 115.45 (HNC=C), 65.57 (CH2) and 18.28, 14.32 (2CH3) ppm. IR (KBr): 1727, 1639, 1620, 1593, 1516, 1462, 1429, 1396, 1381, 1360, 1337, 1316, 1287, 1256, 1247, 1236, 1221, 1204, 1196, 1175, 1159, 1143, 1117, 1084, 1047, 1006, 978, 933, 900, 856, 821, 778, 749, 728, 661, 628, 592, 559, 526, 493, 461, 431, 406, 385, 364, 339 ppm.

Syntheses of compounds 14 and 15

A mixture of 13 (0.01 mol) and o-phenylenediamine or 2-aminophenol (0.01 mol) in acetic acid (25 mL) was fused under reflux for 2–3 h, then cooled and acidified with diluted hydrochloric acid. The resulting solid was filtered off, washed with ethanol, dried and purified by crystallization from ethanol to give 14 and 15.

(E)-5-[1H-benzo[d]imidazole-2-carbonyl]-3-[1-(4-bromophenyl)ethylideneamino]-2-thioxoimidazolidin-4-one 14 Brown crystals, in yield 63%, m.p 238–240 °C.
(E)-5-(Benzo[d]oxazole-2-carbonyl)-3-[1-(4-bromophenyl)ethylideneamino]-2-thioximidazolidin-4-one 15 Pale orange crystals, in yield 65%, m.p 103–105 °C. 1H-NMR (DMSO-d6): δ = 11.99 (s, 1H, NH), 10.26 (s, 1H, NH), 7.91–7.55 (m, 8H, Ar–H), 4.30 (s, 1H, CH) and 2.28 (s, 3H, CH3) ppm. 13C-NMR (DMSO-d6): δ = 178.97 (C=S), 169.08, 167.10 (C=O), 160.27, 146.63 (2C=NC), 136.89, 135.80, 131.56, 130.22, 128.41, 127.30, 123.38, 122.90 (C-aromatic), 73.3 (C) and 14.47 (CH3) ppm. IR (KBr): 3385, 3305 (NH), 1704, 1730 (C=O), 1615 (C=N) and 1393 (C=S) cm−1. MS: m/z (%): 456 (4), 455 (M+, 79Br, 6), 457 (M+, 81Br, 3) and 339 (100). Anal. Calcld. C17H14BrN3O4S (397.33): C, 45.38; H, 3.59; Br, 16.28; N, 8.55; S, 6.50.

Synthesis of (E)-1-acetyl-3-[1-(4-bromophenyl)ethylideneamino]-2-thioximidazolidin-4-one 16 A solution of 1 (0.01 mol) in acetic anhydride (25 mL) was heated under reflux for 2 h, then cooled and the resulting solid was collected by filtration, dried and purified by crystallization from benzene to give compound 16, as white crystals, in yield 88%, m.p 164–166 °C. 1H-NMR (DMSO-d6): δ = 7.59 (d, 2H, J = 8.5 Hz, 2CH), 7.43 (d, 2H, J = 8.5 Hz, 2CH), 4.34 (s, 2H, CH2), 2.23 (s, 3H, CH3) and 2.07 (s, 3H, CH3) ppm. 13C-NMR (DMSO-d6): δ = 172.13 (C=S), 164.75, 163.69 (2C=O), 159.83 (C=N), 137.28, 131.36, 128.42, 122.26 (C-aromatic), 82.16 (CH2), 22.16 (CH3) and 19.47 (CH3) ppm. IR (KBr): 1647, 1716 cm−1 (2C=O), 1600 (C=N) and 1395 (C=S) cm−1. MS: m/z (%): 354 (22), 353 (M+, 79Br, 91) and 355 (M+, 81Br, 100). Anal. Calcld. C17H12BrN2O2S (354.22): C, 44.08; H, 3.41; Br, 22.56; N, 11.86; S, 9.05%. Found. C, 43.92; H, 3.45; Br, 22.64; N, 11.93; S, 9.13.

Synthesis of (E)-1,5-diacyetyl-3-[1-(4-bromophenyl)ethylideneamino]-2-thioximidazolidin-4-one 17 A mixture of 1 (0.01 mol) and fused sodium acetate (0.02 mol) in acetic anhydride (25 mL) was heated under reflux for 3 h, then cooled and poured into ice-water. The resulting solid was filtered off, washed with water, dried and purified by crystallization from benzene to give 17 as pale yellow crystals, in yield 62%, m.p 183–185 °C. 1H-NMR (DMSO-d6): δ = 7.54 (d, 2H, J = 8.5 Hz, 2CH), 7.43 (d, 2H, J = 8.5 Hz, 2CH), 5.08 (s, 1H, CH), 2.25 (s, 3H, CH3), 2.23 (s, 3H, CH3), 2.18 (s, 3H, CH3) ppm. 13C-NMR (DMSO-d6): δ = 169.56 (C=S), 167.85, 164.89, 163.14 (3C=O), 159.85 (C=N), 137.56, 131.42, 128, 28, 122.36 (C-aromatic), 78.00 (CH), 22.48, 22.20 and 18.58 (3CH3). IR (KBr): 1646, 1723 and 1752 (3C=O), 1611 (C=N) and 1397 (C=S) cm−1. MS: m/z (%): 396 (4), 395 (M+, 79Br, 18), 397 (M+, 81Br, 16) and 313 (100). Anal. Calcld. C15H14BrN3O3S (396.26): C, 45.47; H, 3.56; Br, 20.16; N, 10.60; S, 8.09. Found. C, 45.38; H, 3.59; Br, 20.12; N, 10.70; S, 7.98.

Synthesis of (Z)-1-acetyl-3-[1-(4-bromophenyl)ethyldieneamino]-5-(4-hydroxy-3-methoxybenzylidene)-2-thioximidazolidin-4-one 18 A mixture of 16 (0.01 mol), vanillin (0.01 mol) and piperidine (1 mL) was fused on a hot plate at 100–110 °C for half an hour, then ethanol (25 mL) was added and refluxed for 2 h. The reaction mixture then cooled and acidified with diluted hydrochloric acid. The resulting solid was filtered off, washed with water, dried and purified by crystallization from EtOH to give 18 as yellow crystals, in yield 73%, m.p 78–80 °C. 1H-NMR (DMSO-d6): δ = 10.26 (brs, 1H, OH), 7.61–6.95 (m, 8H, Ar–H, CH olefinic), 3.82 (s, 3H, OCH3), 2.32 (s, 3H, CH3) and 2.03 (3, 3H, CH3) ppm. IR (KBr): 3395–3340 (OH), 1751, 1706 (2C=O) groups, 1616 (C=N) and 1396 (C=S) cm−1. MS: m/z (%): 488 (11), 487 (M+, 79Br, 41), 489 (M+, 81Br, 39) and 430 (100). Anal. Calcld. C21H18BrN3O4S (488.35): C, 51.65, H, 3.72; Br, 16.36; N, 8.60; S, 6.57. Found. C, 51.73; H, 3.73; Br, 16.28; N, 8.55; S, 6.50.

Synthesis of (E)-3-[1-(4-bromophenyl)ethyldieneamino]-1-[(diethylamino)methyl]-2-thioximidazolidin-4-one 19 To a solution of 1 (0.01 mol) soluble in 50 mL ethanol was added, a mixture of secondary amines (0.01 mol) (diethylamine) and aqueous formaldehyde 37% (1.25 mL) dissolved in 10 mL ethanol, drop wise throw 30 min, then stirred at room temperature for 3 h. Finally refrigerated for 48 h to form crystals. The solid formed was filtered off and crystallized from ethanol to give compound 19 as pale yellow crystals, in yield 70%, m.p 122–124 °C.

1H-NMR (DMSO-d6): δ = 7.75 (d, 2H, J = 8.5 Hz, 2CH), 7.71 (d, 2H, J = 8.5 Hz, 2CH), 4.55 (s, 2H, CH2), 3.89 (s, 2H, CH2), 2.80 (q, 4H, J = 6.8 Hz, 2CH2), 2.29 (s, 3H, CH3) and 1.08 (t, 6H, J = 6.8 Hz, 2CH3) ppm. IR (KBr): 2820, 2854 (C-aliphatic), 2970 (C-aromatic), 1720 (C=O), 1612 (C=N) and 1384 (C=S) cm−1. MS: m/z (%): 397 (10), 396 (M+, 79Br, 15), 398 (M+, 81Br, 7) and 298 (100). Anal. Calcld. C16H18BrN4O2S (397.33): C, 48.37; H, 5.33; Br, 20.11; N, 14.10; S, 8.07. Found. C, 48.30; H, 5.38; Br, 20.23; N, 13.98; S, 8.14.
Synthesis of (1E,2E)-1,2-bis[1-(4-bromophenyl)ethylidene] hydrazine 20

A mixture of 1 (0.01 mol) and hydrazine hydrate (0.03 mol) was fused on a hot plate at 100–120 °C for half an hour, then adding ethanol (25 mL). The reaction mixture was heated under reflux for 2 h, then poured into ice water and acidified with hydrochloric acid (1 N). The crude product obtained was filtered off, washed with water, dried and purified by crystallization from ethanol to give 20 as white crystals, in yield 78%, m.p. 84–86 °C. 1H-NMR (DMSO-d$_6$): $\delta$ = 7.55 (d, 4H, $J$ = 8.5 Hz, 4CH), 7.47 (d, 4H, $J$ = 8.5 Hz, 4CH) and 2.00 (s, 6H, CH$_3$) ppm. 13C-NMR (DMSO-5-d$_6$): $\delta$ = 140.82 (2C= N), 139.04, 131.00, 126.77, 120.01 (C-aromatic) and 11.19 (2CH$_3$) ppm. MS: m/z (%): 394 (33), 393 (M$^+$, 79Br, 9), 395 (M$^+$, 81Br, 8) and 55 (100). Anal. Calcd. C$_{16}$H$_{14}$Br$_2$N$_2$ (394.10): C, 48.82; H, 131.00, 126.77, 120.01 (C-aromatic) and 11.19 (2CH$_3$) ppm. Found: C, 48.76; H, 3.58; Br, 40.55; N, 7.11. C, 48.82; H, 3.62; Br, 40.39; N, 7.05.

Cytotoxicity Assay

In 96-well plate, the cells were seeded at a cell concentration of $1 \times 10^3$ cells per well in 100 µL of growth medium. Different concentrations from the tested sample were added after 24 h of seeding. The tested compounds underwent serial two-fold dilution, then added to confluent cell monolayers dispensed into 96-well, flat-bottomed microtiter plates (Falcon, NJ, USA) using a multichannel pipette. For a period of 48 h, the microtiter plates were incubated in a humidified incubator with 5% CO$_2$ at 37 °C. For each concentration of the samples, three wells were used. Control cells were incubated without test sample and with or without DMSO. After incubation of the cells at 37 °C, various concentrations of the sample were added, and the incubation was continued for 24 h and viable cells yield was determined by a colorimetric method.

In brief, media were aspirated and the crystal violet solution (1%) was added to each well for at least 30 min after the end of the incubation period. All excess stain is removed, where the plates were rinsed using tap water. To all wells, glacial acetic acid (30%) was then added and mixed thoroughly, and then the absorbance of the plates was measured after gently shaken on the Microplate reader (TECAN, Inc.), using a test wavelength of 490 nm. All results were corrected for background absorbance detected in wells without added stain. Treated samples were compared with the cell control in the absence of the tested compounds. All experiments were carried out in triplicate. The cell cytotoxic effect of each tested compound was calculated. The optical density was measured with the microplate reader (Sunrise, TECAN, Inc, USA) to determine the number of viable cells and the percentage of viability was calculated as $[1 - (ODt/ODc)] \times 100\%$ where ODt is the mean optical density of wells treated with the tested sample and ODC is the mean optical density of untreated cells. The relation between surviving cells and drug concentration is plotted to get the survival curve of each tumor cell line after treatment with the specified compound. The 50% inhibitory concentration (IC50), the concentration required to cause toxic effects in 50% of intact cells, was estimated from graphic plots of the dose–response curve for each conc. using Graphpad Prism software (San Diego, CA. USA).

Additional file

**Supplementary materials (spectroscopic data).**

Authors’ contributions

HAE designed the research and all authors performed the research, analyzed the data and HAE wrote the final manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank King Abdulaziz City for Science and Technology (KACST) for the financial support.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All the relevant data supporting the conclusions of this article is included in the article (Additional file 1).

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Gangadhar SH, Ramesh DK, Mahajan SK (2013) Synthesis, characterization and anticonvulsant activity of 3-substituted 2-thiohydantoin derivatives. IJRPC 3:793–796
2. Wilson LJ, Li M, Portlock OE (1998) Solid phase synthesis of 1-aminohydantoins libraries. Tetrahedron Lett 39:5135–5138
3. Zuliani V, Carmi C, Rivara M, Fantini M, Lodola A, Vacondio F, Bordi F, Plazzi PV, Cavazzoni A, Galetti M, Affieri RR, Petronini PG, Mor M (2009) S-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem 44:3471–3479
4. Yoshino H, Sato H, Shiraiishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H (2010) Design and synthesis of 5-Benzylidene-hydantoins: synthesis and anticonvulsant activity of 3-substituted 2-thiohydantoin derivatives. IJRPC 3:793–796
5. Wilson LJ, Li M, Portlock OE (1998) Solid phase synthesis of 1-aminohydantoins libraries. Tetrahedron Lett 39:5135–5138
6. Zuliani V, Carmi C, Rivara M, Fantini M, Lodola A, Vacondio F, Bordi F, Plazzi PV, Cavazzoni A, Galetti M, Affieri RR, Petronini PG, Mor M (2009) S-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem 44:3471–3479
7. Yoshino H, Sato H, Shiraiishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H (2010) Design and synthesis of 5-Benzylidene-hydantoins: synthesis and anticonvulsant activity of 3-substituted 2-thiohydantoin derivatives. IJRPC 3:793–796
an androgen receptor pure antagonist (CHS137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem 18:8150–8157.

5. Shih CR, Wu J, Liu Y, Liang YC, Lin SY, Sheu MT, Lee WS (2004) Anti-proliferation effect of 5,5'-diphenyl-2-thiohydantoin (DPTH) in human vascular endothelial cells. Biochem Pharm 67:67–75.

6. El-Sharief AM, Moussa Z (2009) Synthesis, characterization and derivatization of some novel types of mono- and bis-imidazolidineiminethiones and imidazolidineiminodithiones with antitumor, antiviral, antibacterial and antifungal activities. Eur J Med Chem 44:4315–4334.

7. Abadi AH, Gary BD, Tinsley HN, Piazza GA, Abdel-Halim M (2010) Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. Eur J Med Chem 45:1278–1286.

8. Moussa Z, El-Sharief AM, Sh El-Sharief M (2011) Synthesis and characterization of new types of halogenated and alkylated imidazolidine-iminethiones and a comparative study of their antitumor, antibacterial, and antifungal activities. Eur J Med Chem 46:2280–2289.

9. Azimohammadi M, Khobi M, Ramazani A, Emami S, Zarrin A, Firuzi O, Miri R, Abbas Shafiee A (2013) 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodamine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 59:15–22.

10. Kiec-Kononowicz K, Szymańska K (2002) Antimycobacterial activity of 5-arylidene derivatives of hydantoin. II Farmaco 57:909–916.

11. Kumar V, Rana H, Sankolli R, Kaushik MP (2012) Novel and efficient protocols for the syntheses of N-1 substituted thiohydantoin and a bicyclohexylhydantoin under solvent-free conditions. Tetrahedron Lett 53:2377–2379.

12. Yildiz I, Bozdag O (2010) Three-dimensional common-feature hypotheses for hypoglycemic flavonol-2,4-thiazolidinedione derivatives. Med Chem Res 19:211–219.

13. Gallienne E, Muccioli GG, Lambert DM, Shipman M (2008) Microwave-assisted four component reaction for the synthesis of a monothiohydantoin inhibitor of a fatty acid amid hydrolase. Tetrahedron Lett 49:6495–6497.

14. Ha YM, Kim JA, Park YJ, Park D, Kim JM, Yoon JH, Moon HR, Chung HY (2011) Analogos of S-(substituted benzylidene) hydantoin as inhibitors of tyrosinase and melanin formation. Biochim Biophys Acta 1810:612–619.

15. Bisquera W, Sumera FC (2011) Regenerable antimicrobial polyurethane coating based on N-hydroxysuccinimidyldihydantoin. Philipp J Sci 140:207–219.

16. Rai N, Kalluraya B, Lingappa B, Shenoy S, Rai N, Kalluraya B, Lingappa B, Shenoy S, Rai N, Kalluraya B, Lingappa B, Shenoy S, Rai N (2009) Microwave-assisted synthesis of some novel pyrimidinons/thions. Indian J Chem 48B:1431–1434.

17. Muccioli GG, Fazio N, Scriba GKE, Poppitz W, Cannata F, Poupaert JH, Wouters J, Lambert DM (2006) Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. J Med Chem 49:417–425.

18. Bouabdallah I, M'Barek LA, Zyed A, Ramdani A, Zidane I, Melhaoui A (2015) A facile synthesis and microtubule-destabilizing properties of 4-(1H-benzo[d]imidazol-2-yl)-furazan-3-amines. Eur J Med Chem 94:237–251.